Practice-and community-based interventions to increase human papillomavirus vaccine coverage a systematic review

JAMA Pediatrics

Volumn 169, Issue 7, 2015, Pages 686-692

  Niccolai, Linda M ^a   Hansen, Caitlin E ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

COMMUNITY CARE; CONSULTATION; DECISION SUPPORT SYSTEM; HEALTH CARE PRACTICE; HEALTH PROGRAM; HUMAN; MEDICAL AUDIT; MEDICAL GEOGRAPHY; MEDICAL PRACTICE; MEDICALLY UNINSURED; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; REVIEW; SOCIAL MARKETING; SYSTEMATIC REVIEW; UNITED STATES; VACCINATION; ADOLESCENT; DEMOGRAPHY; FEMALE; MALE; PAPILLOMAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RESIDENCE CHARACTERISTICS; UNITED STATES; VACCINATION;

EID: 84937458904     PISSN: 21686203     EISSN: 21686211     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2015.0310     Document Type: Review

References (41)

1. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187-193.
2. Syrjänen K, Hakama M, Saarikoski S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis. 1990;17(1):15-19.
3. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157(3):218-226.
4. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819.
5. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis. 2006;33(8):502-508.
6. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011;204(4):566-573.
7. Muñoz N, Bosch FX, de Sanjosé S, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
8. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(suppl 5):F12-F23.
9. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629.
10. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011.MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-1708.
11. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(suppl 5):F123-F138.
12. Stokley S, Jeyarajah J, Yankey D, et al; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep. 2014;63(29): 620-624.
13. Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact ofHPV vaccines: summary of early evidence. J Adolesc Health. 2013;53(6):679-682.
14. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(34): 685-693.
15. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health. 2011;8(2):171-178.
16. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130-135.
17. Public Health England. Annual HPV vaccine coverage in England: 2012-13. http://www.gov.uk/government/uploads/system/uploads/attachment-data/file/266207/HPV-AnnualDataTable2012-13-AT-acc5.pdf. Accessed January 11, 2014.
18. Fu LY, Bonhomme L-A, Cooper SC, Joseph JG, Zimet GD. Educational interventions to increase HPV vaccination acceptance: A systematic review. Vaccine. 2014;32(17):1901-1920.
19. Bundy DG, Persing NM, Solomon BS, et al. Improving immunization delivery using an electronic health record: The Imm Prove project. Acad Pediatr. 2013;13(5):458-465.
20. Cassidy B, Braxter B, Charron-Prochownik D, Schlenk EA. A quality improvement initiative to increase HPV vaccine rates using an educational and reminder strategy with parents of preteen girls. J Pediatr Health Care. 2014;28(2):155-164.
21. Cates JR, Shafer A, Diehl SJ, Deal AM. Evaluating a county-sponsored social marketing campaign to increase mothers' initiation of HPV vaccine for their pre-teen daughters in a primarily rural area. Soc Mar Q. 2011;17(1):4-26.
22. Cates JR, Diehl SJ, Crandell JL, Coyne-Beasley T. Intervention effects from a social marketing campaign to promote HPV vaccination in preteen boys. Vaccine. 2014;32(33):4171-4178.
23. Daley MF, Kempe A, Pyrzanowski J, et al. School-located vaccination of adolescents with insurance billing: cost, reimbursement, and vaccination outcomes. J Adolesc Health. 2014;54 (3):282-288.
24. Fiks AG, Grundmeier RW, Mayne S, et al. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics. 2013;131(6):1114-1124.
25. Gilkey MB, Dayton AM, Moss JL, et al. Increasing provision of adolescent vaccines in primary care: A randomized controlled trial. Pediatrics. 2014;134(2):e346-e353.
26. Kharbanda EO, Stockwell MS, Fox HW, Andres R, LaraM, Rickert VI. Textmessage reminders to promote human papillomavirus vaccination. Vaccine. 2011;29(14):2537-2541.
27. Matheson EC, Derouin A, Gagliano M, Thompson JA, Blood-Siegfried J. Increasing HPV vaccination series completion rates via text message reminders. J Pediatr Health Care. 2014;28(4):e35-e39.
28. Moss JL, Reiter PL, Dayton A, Brewer NT. Increasing adolescent immunization by webinar: A brief provider intervention at federally qualified health centers. Vaccine. 2012;30(33):4960-4963.
29. Stubbs BW, Panozzo CA, Moss JL, Reiter PL, Whitesell DH, Brewer NT. Evaluation of an intervention providing HPV vaccine in schools. Am J Health Behav. 2014;38(1):92-102.
30. Suh CA, Saville A, Daley MF, et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics. 2012;129(6):e1437-e1445.
31. Szilagyi PG, Humiston SG, Gallivan S, Albertin C, Sandler M, Blumkin A. Effectiveness of a citywide patient immunization navigator program on improving adolescent immunizations and preventive care visit rates. Arch Pediatr Adolesc Med. 2011;165(6):547-553.
32. Szilagyi PG, Albertin C, Humiston SG, et al. A randomized trial of the effect of centralized reminder/recall on immunizations and preventive care visits for adolescents. Acad Pediatr. 2013;13(3): 204-213.
33. Szilagyi PG, Bordley C, Vann JC, et al. Effect of patient reminder/recall interventions on immunization rates: A review. JAMA. 2000;284 (14):1820-1827.
34. Bordley WC, Chelminski A, Margolis PA, Kraus R, Szilagyi PG, Vann JJ. The effect of audit and feedback on immunization delivery: A systematic review. Am J Prev Med. 2000;18(4):343-350.
35. Pannaraj PS, Wang H-L, Rivas H, et al. School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. Clin Infect Dis. 2014;59(3):325-332.
36. National Conference of States Legislatures. HPV vaccine policies: Introduced legislation 2013-2014. http://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-statutes.aspx#2013-2014. Accessed September 3, 2014.
37. Perkins RB, Clark JA, Apte G, et al. Missed opportunities for HPV vaccination in adolescent girls: A qualitative study. Pediatrics. 2014;134(3): E666-e674.
38. Rand CM, Szilagyi PG, Albertin C, Auinger P. Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: A national study. Pediatrics. 2007;120(3):461-466.
39. Caskey RN, Macario E, Johnson DC, Hamlish T, Alexander KA. A school-located vaccination adolescent pilot initiative in Chicago: lessons learned. J Pediatr Infect Dis Soc. 2013;2(3):198-204.
40. Kempe A, Barrow J, Stokley S, et al. Effectiveness and cost of immunization recall at school-based health centers. Pediatrics. 2012;129 (6):e1446-e1452.
41. Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- And non-school based immunization program. Vaccine. 2014;32(3):320-326.